SCHEMBL6314654

SCHEMBL6314654

CCN(Cc1ccccc1)c1nc(O)nc(Nc2ccc3ncccc3c2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 4/20 0.59
CRHR1 P34998 3/20 0.45
INSR P06213 1/20 0.44
CSF1R P07333 1/20 0.44
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
KDR P35968 1/20 0.44
TEK Q02763 1/20 0.44
MAPK8 P45983 1/20 0.44
ABCB1 P08183 1/20 0.41
ABCC1 P33527 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
AURKA O14965 2/20 0.41
PABPC1 P11940 1/20 0.41
IGF1R P08069 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395412 0.89 TERT (0.48) TERTKDRMAPK8ABCB1ABCC1
SCHEMBL6399454 0.83 KDR (0.65) TERTCRHR1INSRCSF1RPDGFRB
SCHEMBL6729223 0.77 KDR (0.57) CRHR1INSRCSF1RPDGFRBPDGFRA
SCHEMBL6398204 0.76 KDR (0.56) TERTCRHR1INSRCSF1RPDGFRB
SCHEMBL22292810 0.75 TSHR (0.54) MEN1NPC1POLBMAPTKMT2A
SCHEMBL6395289 0.75 CFTR (0.54) TERTINSRCSF1RPDGFRBPDGFRA
SCHEMBL6404350 0.74 KDR (0.54) CRHR1INSRCSF1RPDGFRBPDGFRA
SCHEMBL6314646 0.74 AURKA (0.54) TERTMAPK8ABCB1ABCC1ABCG2
SCHEMBL6394106 0.72 KDR (0.52) CRHR1INSRCSF1RPDGFRBPDGFRA
SCHEMBL6393984 0.72 KDR (0.56) TERTINSRCSF1RPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP claimed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US claimed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO claimed
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP disclosed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 TERT 1021/4885CRHR1 2037/4885INSR 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.